Gloucester raises $29 million to fund lymphoma drug
This article was originally published in Scrip
Executive Summary
Gloucester Pharmaceuticals of the US has raised $29 million in a series D financing. The proceeds will be used to fund the ongoing development of Istodax (romidepsin), a novel histone deacetylase (HDAC) inhibitor for the treatment of T-cell lymphomas and other haematological malignancies.